Today, ATAI Life Sciences, a global biotech platform that envisions an end to mental illnesses, announced the appointment of Dr. Terence Kelly as Chief Executive Officer of Perception Neuroscience, an ATAI biopharmaceutical company developing arketamine for treatment resistant depression.
Terence Kelly appointed CEO of ATAI platform company Perception Neuroscience
atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)
atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced…
JOIN THE ATAI #INSIGHTNETWORK